bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 4 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Independent predictors of FGFR1/3 fusions in 1328 patients with NSCLCs in multivariate analysis
Supplementary Table 2 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file - 80KB, Detailed Clinicopathologic Characteristics of 1328 patients with non-small cell lung cancer.
Suplpementary Figure 1 from Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group
Authors: Hingorani Pooja , Missiaglia Edoardo , Shipley Janet , Anderson James R. , Triche Timothy J. , Delorenzi Mauro , Gastier-Foster Julie , Wing Michele , Hawkins Douglas S. , Skapek Stephen X.
Published: April 2023

Plot of the mean expression versus the standard deviation (SD) of all the genes included in (A) ITCC/CIT dataset (Affy HGU133plus2 platform) or (B) COG/IRSG dataset (Affy HGU133a platform). Genes included in the nCounter assay were colored in blue or in red (if their SD was below 0.6). C) Plot of the mean expression of the selected genes in the two datasets. Excluding NDUFS4, the other genes showed similar level of expression across datasets.
Supplementary Table 2 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Detailed Clinicopathologic Characteristics of 1328 patients with non-small cell lung cancer.
Supplementary Table 1 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Primers Used for Sequencing of FGFR Fusion
Supplementary Table S1 to Table S5 from Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
Authors: Kong Yan , Si Lu , Li Yiqian , Wu Xiaowen , Xu Xiaowei , Dai Jie , Tang Huan , Ma Meng , Chi Zhihong , Sheng Xinan , Cui Chuanliang , Guo Jun
Published: April 2023

Supplementary Table S1. Primers used for nested PCR amplification of exons and for sequencing; Supplementary Table S2. Detailed clinicopathological characteristics of melanoma patients and the detected mTOR aberrations; Supplementary Table S3. Confirmation of mTOR nonsynonymous mutations in fresh melanoma tissues using Agilent's SureSelect Target Enrichment System; Supplementary Table S4. Gene aberrations of validated targets in melanoma samples showing mTOR nonsynonymous mutations; Supplementary Table S5. Correlation of mTOR nonsynonymous mutation to activation of PI3K-AKT-mTOR pathway.
Supplementary Figure 3 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

PDF file - 47KB, Kaplan-Meier survival curves for relapse free and overall survival according to EGFR, KRAS, BRAF, HER2, FGFR or wild-type status.
Supplementary Table 2 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Authors: Magbanua Mark Jesus M. , Carey Lisa A. , DeLuca Amy , Hwang Jimmy , Scott Janet H. , Rimawi Mothaffar F. , Mayer Erica L. , Marcom P. Kelly , Liu Minetta C. , Esteva Francisco J. , Park John W. , Rugo Hope S.
Published: April 2023

Supplementary Table 2. Median overall survival (OS) and time-to-progression (TTP) in months for different groups based on CTC status. Patients were assigned to the following groups: favorable (
Supplementary Figure S2: 14 mutational signatures from Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Authors: Nik-Zainal Serena , Morganella Sandro
Published: April 2023

Supplementary Figure S2: 14 signatures
Supplementary Table 2 from A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Authors: Zauderer Marjorie G. , Tsao Anne S. , Dao Tao , Panageas Katherine , Lai W. Victoria , Rimner Andreas , Rusch Valerie W. , Adusumilli Prasad S. , Ginsberg Michelle S. , Gomez Daniel , Rice David , Mehran Reza , Scheinberg David A. , Krug Lee M.
Published: April 2023

Displays historical survival from multimodality cohorts that were used to set expected outcomes.
Supplementary Information from Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations
Authors: Friedman Adam A. , Xia Yun , Trippa Lorenzo , Le Long Phi , Igras Vivien , Frederick Dennie T. , Wargo Jennifer A. , Tanabe Kenneth K. , Lawrence Donald P. , Neuberg Donna S. , Flaherty Keith T. , Fisher David E.
Published: April 2023

Supplementary Figures and Figure Legends
Supplementary Figures 1a and 1b from A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Authors: Zauderer Marjorie G. , Tsao Anne S. , Dao Tao , Panageas Katherine , Lai W. Victoria , Rimner Andreas , Rusch Valerie W. , Adusumilli Prasad S. , Ginsberg Michelle S. , Gomez Daniel , Rice David , Mehran Reza , Scheinberg David A. , Krug Lee M.
Published: April 2023

Data from an individual patient showing immune response to vaccine and native WT1 peptides.
Supplementary Figure 8 from Personalized Medicine–Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids
Authors: Raghavan Shreya , Mehta Pooja , Ward Maria R. , Bregenzer Michael E. , Fleck Elyse M. A. , Tan Lijun , McLean Karen , Buckanovich Ronald J. , Mehta Geeta
Published: April 2023

Supplementary Figure 8: Drug dose response of cisplatin, 673A, and ruxolitinib on monolayer cultures of Pt259 OvCSCs
Supplementary Table S1. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Authors: Giró-Perafita Ariadna , Palomeras Sònia , Lum David H. , Blancafort Adriana , Viñas Gemma , Oliveras Glòria , Pérez-Bueno Ferran , Sarrats Ariadna , Welm Alana L. , Puig Teresa
Published: April 2023

TNBC Patients demographics and clinical characteristics (n=26).
Supplementary Figure S7. Total volume data for EGCG plus cetuximab in sensitive and resistant TNBC ortoxenograft. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Authors: Giró-Perafita Ariadna , Palomeras Sònia , Lum David H. , Blancafort Adriana , Viñas Gemma , Oliveras Glòria , Pérez-Bueno Ferran , Sarrats Ariadna , Welm Alana L. , Puig Teresa
Published: April 2023

(A) Mice bearing 231 and (B) 231DXR xenografts were treated with saline (Control), EGCG (30mg/Kg, 3 days a week), cetuximab (0.5mg/mice 1 day a week) or the combination (EGCG plus cetuximab) for 12 days. (C) Mice bearing HCC and (D) HCCDXR xenografts were treated with saline (Control), EGCG (30mg/Kg, 3 days a week), cetuximab (100uL/mice 1 day a week) or the combination (EGCG plus cetuximab) for 10 days. Total volume is shown as (Final Volume - Initial Volume). Dots are mean of each experimental group and bars, SEM. *(p < 0.05), **(p < 0.01) and ***(p < 0.001) indicate levels of statistically significance.
Supplementary Figure S6. Cell proliferation inhibition of cetuximab and FASN inhibitors EGCG and C75 in doxorubicin resistant cells from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Authors: Giró-Perafita Ariadna , Palomeras Sònia , Lum David H. , Blancafort Adriana , Viñas Gemma , Oliveras Glòria , Pérez-Bueno Ferran , Sarrats Ariadna , Welm Alana L. , Puig Teresa
Published: April 2023

cells (A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of cetuximab (0,5 - 4 µM), C75 (20 - 60 µM) or EGCG ( 25 - 150 µM) for 4 days. Results are expressed as mean {plus minus} SEM. Experiments were performed at least three times in triplicate. *(p < 0.05), **(p < 0.01) and ***(p < 0.001) indicate levels of statistically significance.
Supplementary Figure S2. Cell proliferation inhibition in parental and doxorubicin resistant derivate. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Authors: Giró-Perafita Ariadna , Palomeras Sònia , Lum David H. , Blancafort Adriana , Viñas Gemma , Oliveras Glòria , Pérez-Bueno Ferran , Sarrats Ariadna , Welm Alana L. , Puig Teresa
Published: April 2023

(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of doxorubicin (50 - 350 nM) for 48h. Experiments were performed three times in triplicate. Results shown are mean {plus minus} SEM. *(p < 0.05), **(p < 0.01) and ***(p < 0.001) indicate levels of statistically significance.
Supplementary Figure S1. FASN and EGFR mRNA levels in a panel of TNBC cell lines. from Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Authors: Giró-Perafita Ariadna , Palomeras Sònia , Lum David H. , Blancafort Adriana , Viñas Gemma , Oliveras Glòria , Pérez-Bueno Ferran , Sarrats Ariadna , Welm Alana L. , Puig Teresa
Published: April 2023

(A) FASN and (B) EGFR mRNA levels were obtained by Real-Time PCR and normalized against the β-actin gene. Results shown are mean {plus minus} SEM from 3 independent experiments.
Supplemental Figure Legends from Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen
Authors: Brechbuhl Heather M. , Finlay-Schultz Jessica , Yamamoto Tomomi M. , Gillen Austin E. , Cittelly Diana M. , Tan Aik-Choon , Sams Sharon B. , Pillai Manoj M. , Elias Anthony D. , Robinson William A. , Sartorius Carol A. , Kabos Peter
Published: April 2023

Supplemental Figure Legends.
Supplementary Figure 3 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Authors: Connolly Roisin M. , Li Huili , Jankowitz Rachel C. , Zhang Zhe , Rudek Michelle A. , Jeter Stacie C. , Slater Shannon A. , Powers Penny , Wolff Antonio C. , Fetting John H. , Brufsky Adam , Piekarz Richard , Ahuja Nita , Laird Peter W. , Shen Hui , Weisenberger Daniel J. , Cope Leslie , Herman James G. , Somlo George , Garcia Agustin A. , Jones Peter A. , Baylin Stephen B. , Davidson Nancy E. , Zahnow Cynthia A. , Stearns Vered
Published: April 2023

Gene list and biological pathways of significant differentially expressed genes in hormone-resistant breast cancer volcano plot.
Figure S1 from A Zebrafish Model Discovers a Novel Mechanism of Stromal Fibroblast-Mediated Cancer Metastasis
Authors: Liu Caifeng , Zhang Yunjian , Lim Sharon , Hosaka Kayoko , Yang Yunlong , Pavlova Tatiana , Alkasalias Twana , Hartman Johan , Jensen Lasse , Xing Xiaoming , Wang Xinsheng , Lu Yongtian , Nie Guohui , Cao Yihai
Published: April 2023

Human CRC tumor fibrosis and isolation of CAFs
Supplementary Figure 1 from Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells
Authors: Guillotin Delphine , Austin Philip , Begum Rumena , Freitas Marta O. , Merve Ashirwad , Brend Tim , Short Susan , Marino Silvia , Martin Sarah A.
Published: April 2023

Supplementary figure 1 describes how Triamterene requires thymidylate synthase expression to induce selectivity in MMR -deficient cells. Related to Figure 2.
Figure S4 from Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component
Authors: Avigdor Bracha Erlanger , Beierl Katie , Gocke Christopher D. , Zabransky Daniel J. , Cravero Karen , Kyker-Snowman Kelly , Button Berry , Chu David , Croessmann Sarah , Cochran Rory L. , Connolly Roisin M. , Park Ben H. , Wheelan Sarah J. , Cimino-Mathews Ashley
Published: April 2023

Supplemental figure S4
Supplemental Figure 1A from Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma
Authors: Poruk Katherine E. , Blackford Amanda L. , Weiss Matthew J. , Cameron John L. , He Jin , Goggins Michael , Rasheed Zeshaan A. , Wolfgang Christopher L. , Wood Laura D.
Published: April 2023

Staining of primary tumors by immunohistochemistry demonstrating (A) strong staining of ALDH
Figure S3 from Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component
Authors: Avigdor Bracha Erlanger , Beierl Katie , Gocke Christopher D. , Zabransky Daniel J. , Cravero Karen , Kyker-Snowman Kelly , Button Berry , Chu David , Croessmann Sarah , Cochran Rory L. , Connolly Roisin M. , Park Ben H. , Wheelan Sarah J. , Cimino-Mathews Ashley
Published: April 2023

Supplemental figure S3
Supplementary Figures 1-2 from Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers
Authors: Möhrmann Lino , Huang Helen J. , Hong David S. , Tsimberidou Apostolia M. , Fu Siqing , Piha-Paul Sarina A. , Subbiah Vivek , Karp Daniel D. , Naing Aung , Krug Anne , Enderle Daniel , Priewasser Tina , Noerholm Mikkel , Eitan Erez , Coticchia Christine , Stoll Georg , Jordan Lisa-Marie , Eng Cathy , Kopetz E. Scott , Skog Johan , Meric-Bernstam Funda , Janku Filip
Published: April 2023

Supplementary Fig. 1. Isolation of exosomes by spin-column purification; Supplementary Fig. 2. The median survival time of 25 patients with RMH scores of 0 or 1 (dashed blue line; 8.4 months; 95% CI, 6.0-10.8 months) was significantly longer than that of 18 patients with RMH scores of 2 or 3 (red line; 6.0 months; 95% CI, 2.3-9.7 months; P=0.017).
Figures S1-S8 from Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Authors: Messenheimer David J. , Jensen Shawn M. , Afentoulis Michael E. , Wegmann Keith W. , Feng Zipei , Friedman David J. , Gough Michael J. , Urba Walter J. , Fox Bernard A.
Published: April 2023

Figure S1 shows combination treatment induces splenomegaly and T cells Apoptosis Figure S2 shows PD-L1 is increased on splenic T cells with combination treatment Figure S3 shows combination treatment increases costimulatory receptors on T cells Figure S4 shows delayed anti-PD-1 and anti-PD-L1 are ineffective at tumor control Figure S5 shows sequential combination provides anti-tumor immunity in the 4T1 model. Figure S6 shows sequential combination does not induce inflammatory cytokines Figure S7 shows sequential combination does not increase costimulatory receptors Figure S8 shows combination treatment induces functional PyMT-specific T cells
SFigure 2 from Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Authors: Müller-Greven Gaëlle , Carlin Cathleen R. , Burgett Monica E. , Ahluwalia Manmeet S. , Lauko Adam , Nowacki Amy S. , Herting Cameron J. , Qadan Maha A. , Bredel Markus , Toms Steven A. , Lathia Justin D. , Hambardzumyan Dolores , Sarkaria Jann N. , Hamerlik Petra , Gladson Candece L.
Published: April 2023

Figure S2 shows the internalization of bevacizumab by CD133-negative non-stem GBM tumor cells was not inhibited by EIPA.
Supplementary Figures 1-5, Supplementary Table 1 from Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion
Authors: Ng Sinnie Sin Man , Nagy Bethany A. , Jensen Shawn M. , Hu Xintao , Alicea Candido , Fox Bernard A. , Felber Barbara K. , Bergamaschi Cristina , Pavlakis George N.
Published: April 2023

Supplementary Figure 1. IL-15 availability promotes proliferation and maintenance of transferred CD8+ T in the spleen of recipient mice; Supplementary Figure 2. Gating strategy for the identification of adoptively transferred Pmel-1 cells and endogenous CD8+ T cells infiltrating the tumor; Supplementary Figure 3. Absolute counts of splenic Pmel-1 and CD8+ T cells are profoundly affected by hetIL-15 treatment; Supplementary Figure 4. Evaluation of PD-1, Ki67 and GzmB expression by tumorinfiltrating Pmel-1 cells; Supplementary Figure 5. Evaluation of PD-1, Ki67 and GzmB expression by tumorinfiltrating CD8+ T cells; Supplementary Table 1. Hematological parameters during ACT treatments.
Supplementary Tables S11 and S12 from The Genomic Landscape of Male Breast Cancers
Authors: Piscuoglio Salvatore , Ng Charlotte K.Y. , Murray Melissa P. , Guerini-Rocco Elena , Martelotto Luciano G. , Geyer Felipe C. , Bidard Francois-Clement , Berman Samuel , Fusco Nicola , Sakr Rita A. , Eberle Carey A. , De Mattos-Arruda Leticia , Macedo Gabriel S. , Akram Muzaffar , Baslan Timour , Hicks James B. , King Tari A. , Brogi Edi , Norton Larry , Weigelt Britta , Hudis Clifford A. , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S11: Comparative analysis of the frequencies of mutations in luminal A-like male breast cancers and subsets of luminal A female breast cancers from the TCGA study. Supplementary Table S12: Comparative analysis of the frequencies of mutations in luminal B-like male breast cancers and subsets of luminal B female breast cancers from the TCGA study.
Supplemental Figure S1 from Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy
Authors: Kim Kwanghee , Zhang Hanwen , La Rosa Stephen , Jebiwott Sylvia , Desai Pooja , Kimm Simon , Scherz Avigdor , O'Donoghue Joseph A. , Weber Wolfgang A. , Coleman Jonathan A.
Published: April 2023

Kidneys and pancreas from mice bearing PC-3 tumors in 4 different treatment groups (n= 5 per each treatment group) were collected at 41 days post treatment and subjected for H&E staining to determine potential tissue toxicity caused by 90Y-DOTA-AR/VTP combination therapy. No significant lesions and no evidence of treatment induced lesions were observed in these organs (representative H&E pictures shown).
Supplementary Figures S1-S3 from The Genomic Landscape of Male Breast Cancers
Authors: Piscuoglio Salvatore , Ng Charlotte K.Y. , Murray Melissa P. , Guerini-Rocco Elena , Martelotto Luciano G. , Geyer Felipe C. , Bidard Francois-Clement , Berman Samuel , Fusco Nicola , Sakr Rita A. , Eberle Carey A. , De Mattos-Arruda Leticia , Macedo Gabriel S. , Akram Muzaffar , Baslan Timour , Hicks James B. , King Tari A. , Brogi Edi , Norton Larry , Weigelt Britta , Hudis Clifford A. , Reis-Filho Jorge S.
Published: April 2023

Supplementary Figure 1: Validation of somatic mutations in orthogonal methods. Supplementary Figure S2: Mutations and copy number alterations in ER-positive/HER2-negative male and female breast cancers. Supplementary Figure S3: Cancer cell fraction and clonality of non-synonymous mutations in male breast cancer.
Figure S6 from Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Authors: Li Si , Siriwon Natnaree , Zhang Xiaoyang , Yang Shuai , Jin Tao , He Feng , Kim Yu Jeong , Mac John , Lu Zhengfei , Wang Sijie , Han Xiaolu , Wang Pin
Published: April 2023

Both CAR19 and CAR19.Î±PD1 T cells were cocultured with H292-CD19 cells for 24 hours. (A) The expression of PD-1, LAG-3 and TIM-3 was measured by flow cytometry. The percentage of PD-1-, LAG-3- or TIM-3-expressing CD4 T cells over total CD4+ T cells was shown in bar graphs (n=3, mean {plus minus} SEM; ns, not significant, P > 0.05; **P < 0.01). (B) The expression of PD-1 and LAG-3 in both CAR19 and CAR19.Î±PD1 T cells during the course of T cell expansion (post T cell activation and transduction).
Supplemental Table 1 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Authors: Wang Xiuli , Walter Miriam , Urak Ryan , Weng Lihong , Huynh Christian , Lim Laura , Wong ChingLam W. , Chang Wen-Chung , Thomas Sandra H. , Sanchez James F. , Yang Lu , Brown Christine E. , Pichiorri Flavia , Htut Myo , Krishnan Amrita Y. , Forman Stephen J.
Published: April 2023

Taqman probes used in qPCR
Figure S3 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Authors: Gainor Justin F. , Shaw Alice T. , Sequist Lecia V. , Fu Xiujun , Azzoli Christopher G. , Piotrowska Zofia , Huynh Tiffany G. , Zhao Ling , Fulton Linnea , Schultz Katherine R. , Howe Emily , Farago Anna F. , Sullivan Ryan J. , Stone James R. , Digumarthy Subba , Moran Teresa , Hata Aaron N. , Yagi Yukako , Yeap Beow Y. , Engelman Jeffrey A. , Mino-Kenudson Mari
Published: April 2023

Immunohistochemical Analysis of CD8+ Tumor Infiltrating Lymphocytes. Representative images of CD8 scoring: 0 (A), 1+ (B), 2+ (C), and 3+ (D).
Figure S2 from EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Authors: Gainor Justin F. , Shaw Alice T. , Sequist Lecia V. , Fu Xiujun , Azzoli Christopher G. , Piotrowska Zofia , Huynh Tiffany G. , Zhao Ling , Fulton Linnea , Schultz Katherine R. , Howe Emily , Farago Anna F. , Sullivan Ryan J. , Stone James R. , Digumarthy Subba , Moran Teresa , Hata Aaron N. , Yagi Yukako , Yeap Beow Y. , Engelman Jeffrey A. , Mino-Kenudson Mari
Published: April 2023

PD-L1 Immunohistochemical Analysis. Representative images of negative PD-L1 expression (A), {greater than or equal to}1%, <5% PD-L1 expression (B), {greater than or equal to}5%, <50% PD-L1 expression (C) and {greater than or equal to}50% PD-L1 expression (D) on FFPE samples.
Supplemental Figure 6 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Flow cytometry analysis of M1/M2 macrophage polarization post tumor resection and IFNÃŽÂ² treatment in CT2A tumor bearing mouse brains
Supplemental Figure 3 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Flow cytometry analysis of immune cell population in CT2A tumor bearing mouse brains
Supplemental Figure 2 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Establishment of mouse model of Gl261 tumor resection
Supplemental Figure 1 from Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas
Authors: Choi Sung Hugh , Stuckey Daniel W. , Pignatta Sara , Reinshagen Clemens , Khalsa Jasneet Kaur , Roozendaal Nicolaas , Martinez-Quintanilla Jordi , Tamura Kaoru , Keles Erhan , Shah Khalid
Published: April 2023

Tumor growth can be monitored by Fluc signal of CT2A-FmC and GL261-FmC lines
Figure S1, Figure S2, Figure S3, Figure S4 from Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain
Authors: Priceman Saul J. , Tilakawardane Dileshni , Jeang Brook , Aguilar Brenda , Murad John P. , Park Anthony K. , Chang Wen-Chung , Ostberg Julie R. , Neman Josh , Jandial Rahul , Portnow Jana , Forman Stephen J. , Brown Christine E.
Published: April 2023

Figure S1: HER2 expression in BBM1 tumors. (a) Representative histology of HER2 expression in BBM1 tumors engrafted in mouse brain. N = normal brain, T = BBM1 tumor. Figure S2: Intraventricular HER2-BBζ CAR T cell therapy is effective against BBM1 tumors. Figure S3: Intraventricular HER2-BBζ CAR T cell therapy is effective against HER2+ BT474 tumors, but not HER2- MDA-MB-468 tumors. Figure S4: CD4 and CD8 CAR T cell infiltrates in BBM1 tumors.
Supplementary Table 4 from Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Authors: Wood Andrew C. , Krytska Kateryna , Ryles Hannah T. , Infarinato Nicole R. , Sano Renata , Hansel Theodore D. , Hart Lori S. , King Frederick J. , Smith Timothy R. , Ainscow Edward , Grandinetti Kathryn B. , Tuntland Tove , Kim Sunkyu , Caponigro Giordano , He You Qun , Krupa Shiva , Li Nanxin , Harris Jennifer L. , Mossé Yaël P.
Published: April 2023

Complete dataset for synergy screen.
Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Authors: Ascierto Maria L. , Makohon-Moore Alvin , Lipson Evan J. , Taube Janis M. , McMiller Tracee L. , Berger Alan E. , Fan Jinshui , Kaunitz Genevieve J. , Cottrell Tricia R. , Kohutek Zachary A. , Favorov Alexander , Makarov Vladimir , Riaz Nadeem , Chan Timothy A. , Cope Leslie , Hruban Ralph H. , Pardoll Drew M. , Taylor Barry S. , Solit David B. , Iacobuzio-Donahue Christine A. , Topalian Suzanne L.
Published: April 2023

Functionally annotated gene categories from DAVID analysis of Illumina probes differentially expressed between regressing vs. progressing melanoma metastases
Supplemental Figure Legend from Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Authors: Kim Joo Young , Brosnan-Cashman Jacqueline A. , An Soyeon , Kim Sung Joo , Song Ki-Byung , Kim Min-Sun , Kim Mi-Ju , Hwang Dae Wook , Meeker Alan K. , Yu Eunsil , Kim Song Cheol , Hruban Ralph H. , Heaphy Christopher M. , Hong Seung-Mo
Published: April 2023

Supplemental Figure 1. (A) ALT-positive PanNET patients with lymph node metastasis (median survival, 131 months) had a tendency of better survival than ALT-negative PanNET patients with nodal metastasis (54 months, HR=0.31, 95% CI=0.08-1.19; p=0.088). (B) ALT-positive PanNET patients with distant metastasis (overall 5-year survival rate, 75.0%) trended toward better survival than ALT-negative patients (25.0%), but was not statistically significant (p=0.118).
Supplementary Table S1 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Authors: Ascierto Maria L. , Makohon-Moore Alvin , Lipson Evan J. , Taube Janis M. , McMiller Tracee L. , Berger Alan E. , Fan Jinshui , Kaunitz Genevieve J. , Cottrell Tricia R. , Kohutek Zachary A. , Favorov Alexander , Makarov Vladimir , Riaz Nadeem , Chan Timothy A. , Cope Leslie , Hruban Ralph H. , Pardoll Drew M. , Taylor Barry S. , Solit David B. , Iacobuzio-Donahue Christine A. , Topalian Suzanne L.
Published: April 2023

Whole exome sequencing data, including somatic variants, purities, private mutations, and predicted neoantigens.
Supplemental Figure 1 from Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Authors: Kim Joo Young , Brosnan-Cashman Jacqueline A. , An Soyeon , Kim Sung Joo , Song Ki-Byung , Kim Min-Sun , Kim Mi-Ju , Hwang Dae Wook , Meeker Alan K. , Yu Eunsil , Kim Song Cheol , Hruban Ralph H. , Heaphy Christopher M. , Hong Seung-Mo
Published: April 2023

(A) ALT-positive PanNET patients with lymph node metastasis (median survival, 131 months) had a tendency of better survival than ALT-negative PanNET patients with nodal metastasis (54 months, HR=0.31, 95% CI=0.08-1.19; p=0.088). (B) ALT-positive PanNET patients with distant metastasis (overall 5-year survival rate, 75.0%) trended toward better survival than ALT-negative patients (25.0%), but was not statistically significant (p=0.118).
Supplementary Figures 1, 2, 3 from Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Authors: Trivedi Sumita , Srivastava Raghvendra M. , Concha-Benavente Fernando , Ferrone Soldano , Garcia-Bates Tatiana M. , Li Jing , Ferris Robert L.
Published: April 2023

Sup Fig 1. Patient demographic data for clinical trials UPCI 08-013 and UPCI 06-120. Sup Fig 2.Flow cytometric plots from representative donor PBMC showing percentages of CD14+ and CD56+ Sup Fig 3. Flow cytometric histogram illustrating the relative EGFR expression
Table S4 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Authors: Patel Sohil H. , Poisson Laila M. , Brat Daniel J. , Zhou Yueren , Cooper Lee , Snuderl Matija , Thomas Cheddhi , Franceschi Ana M. , Griffith Brent , Flanders Adam E. , Golfinos John G. , Chi Andrew S. , Jain Rajan
Published: April 2023

RPPA results comparing protein levels between the 125 TCGA/TCIA gliomas differentiated by the T2-FLAIR mismatch sign.
Figure S2 from T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
Authors: Patel Sohil H. , Poisson Laila M. , Brat Daniel J. , Zhou Yueren , Cooper Lee , Snuderl Matija , Thomas Cheddhi , Franceschi Ana M. , Griffith Brent , Flanders Adam E. , Golfinos John G. , Chi Andrew S. , Jain Rajan
Published: April 2023

Kaplan-Meier curves demonstrating progression free survival and overall survival associated with the LGGs from the TCGA/TCIA database. Blue curves represent IDHmut-Codel gliomas, dotted black curves represent IDHmut-Noncodel gliomas that were positive for the T2-FLAIR mismatch sign, solid black curves represent IDHmut-Noncodel gliomas that were negative for the T2-FLAIR mismatch sign, and red curves represent IDHwt gliomas.
Supplemental Figure 1. Age, gender, MCPyV status and perineural invasion do not correlate with disease specific survival in MCC. from Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
Authors: Feldmeyer Laurence , Hudgens Courtney W. , Ray-Lyons Genevieve , Nagarajan Priyadharsini , Aung Phyu P. , Curry Jonathan L. , Torres-Cabala Carlos A. , Mino Barbara , Rodriguez-Canales Jaime , Reuben Alexandre , Chen Pei-Ling , Ko Jennifer S. , Billings Steven D. , Bassett Roland L. , Wistuba Ignacio I. , Cooper Zachary A. , Prieto Victor G. , Wargo Jennifer A. , Tetzlaff Michael T.
Published: April 2023

(A) Kaplan-Meier plot for age and disease specific survival applying a cut off of 71y. (B) Kaplan-Meier plot for sex and disease specific survival. (C) Kaplan-Meier plot for MCPyV status and disease specific survival. (D) Kaplan-Meier plot for perineural invasion and disease specific survival.
Figure S1 to S7; table S1 from BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer
Authors: Gong Chun , Man Ellen P.S. , Tsoi Ho , Lee Terence K.W. , Lee Paul , Ma Sai-Ting , Wong Lai-San , Luk Mai-Yee , Rakha Emad A. , Green Andrew R. , Ellis Ian O. , Lam Eric W.-F. , Cheung Kwok-Leung , Khoo Ui-Soon
Published: April 2023

Supplementary figure 1. BQ323636.1-overexpresion stable cell lines were produced using lentiviral system; Supplementary figure 2. BQ323636.1 overexpression conferred resistance to tamoxifen in vivo using xenografts established with MCF-7; Supplementary figure 3. BQ323636.1 overexpressed did not significantly affect the expressions of NCOR2, GPS2, TBLR1 nor HDAC3; Supplementary figure 4. Chromatin Immunoprecipitation (ChIP) assays show overexpression of BQ323636.1 could reduce the amount of NCOR2 interacting with estrogen responsive element of four genes; Supplementary figure 5. The clinical significance of nuclear expression level of BQ323636.1 in the Hong Kong cohort.; Supplementary figure 6. The clinical significance of nuclear expression level of BQ323636.1 in the United Kingdom cohort; Supplementary figure 7. The significance of nuclear expression level of BQ323636.1 on disease free survival.; Supplementary Table 1. Clinical characteristics of patients with Tamoxifen response information available, N= 358
Supplementary Data from Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Authors: Olmez Inan , Brenneman Breanna , Xiao Aizhen , Serbulea Vlad , Benamar Mouadh , Zhang Ying , Manigat Laryssa , Abbas Tarek , Lee Jeongwu , Nakano Ichiro , Godlewski Jakub , Bronisz Agnieszka , Abounader Roger , Leitinger Norbert , Purow Benjamin
Published: April 2023

Supplementary Figure S1. Mutations in CCND3 increase sensitivity to mTOR inhibition. Supplementary Figure S2. Dose-response plots for everolimus and palbociclib. Supplementary Figure S3. mTOR inhibition with everolimus cross-regulates the CDK/Rb pathway. Supplementary Figure S4. Erk activity is linked to CDK4/6 inhibition. Supplementary Figure S5. Palbociclib treatment decreases the phosphorylation of Erk1/2. Supplementary Figure S6. Cells remain attached throughout the Seahorse metabolic assays. Supplementary Figure S7. Immunohistochemistry staining of tumor harboring mouse brains for GIC markers.
Supplemental Figure S6B from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

Tetramer plots used to determine PR1-CTL frequency in peripheral blood of multiple myeloma patients following allogenic stem cell transplantation
Supplemental Figure S5 from Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma
Authors: Alatrash Gheath , Perakis Alexander A. , Kerros Celine , Peters Haley L. , Sukhumalchandra Pariya , Zhang Mao , Jakher Haroon , Zope Madhushree , Patenia Rebecca , Sergeeva Anna , Yi Shuhua , Young Ken H. , Philips Anne V. , Cernosek Amanda M. , Garber Haven R. , Qiao Na , Weng Jinsheng , St John Lisa S. , Lu Sijie , Clise-Dwyer Karen , Mittendorf Elizabeth A. , Ma Qing , Molldrem Jeffrey J.
Published: April 2023

U266 cross-presents PR1 after exposure to NE/P3 from PMN co-culture
Supplemental Figure Legends from Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect
Authors: Scroggins Bradley T. , Matsuo Masayuki , White Ayla O. , Saito Keita , Munasinghe Jeeva P. , Sourbier Carole , Yamamoto Kazutoshi , Diaz Vivian , Takakusagi Yoichi , Ichikawa Kazuhiro , Mitchell James B. , Krishna Murali C. , Citrin Deborah E.
Published: April 2023

Supplemental Figure Legends
Table S5-S7 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Authors: Zhang Wei , Liu Bo , Wu Wenhui , Li Likun , Broom Bradley M. , Basourakos Spyridon P. , Korentzelos Dimitrios , Luan Yang , Wang Jianxiang , Yang Guang , Park Sanghee , Azad Abul Kalam , Cao Xuhong , Kim Jeri , Corn Paul G. , Logothetis Christopher J. , Aparicio Ana M. , Chinnaiyan Arul M. , Navone Nora , Troncoso Patricia , Thompson Timothy C.
Published: April 2023

Table S5. Primer Sequences for qRT-PCR. Table S6. siRNA Sequence. Table S7. Primer Sequences for ChIP-PCR.
Table S3 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Authors: Zhang Wei , Liu Bo , Wu Wenhui , Li Likun , Broom Bradley M. , Basourakos Spyridon P. , Korentzelos Dimitrios , Luan Yang , Wang Jianxiang , Yang Guang , Park Sanghee , Azad Abul Kalam , Cao Xuhong , Kim Jeri , Corn Paul G. , Logothetis Christopher J. , Aparicio Ana M. , Chinnaiyan Arul M. , Navone Nora , Troncoso Patricia , Thompson Timothy C.
Published: April 2023

Differential expression results for DDR-M genes in Beltran's and MDA PDX RNAseq datasets.
Figure S2 from Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients
Authors: Drögemöller Britt I. , Brooks Beth , Critchley Carol , Monzon José G. , Wright Galen E.B. , Liu Geoffrey , Renouf Daniel J. , Kollmannsberger Christian K. , Bedard Philippe L. , Hayden Michael R. , Gelmon Karen A. , Carleton Bruce C. , Ross Colin J.D.
Published: April 2023

Figure S2 provides a visualization of the hearing thresholds of patients grouped by ACYP2 and WFS1 genotype
Figure S1 from Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients
Authors: Drögemöller Britt I. , Brooks Beth , Critchley Carol , Monzon José G. , Wright Galen E.B. , Liu Geoffrey , Renouf Daniel J. , Kollmannsberger Christian K. , Bedard Philippe L. , Hayden Michael R. , Gelmon Karen A. , Carleton Bruce C. , Ross Colin J.D.
Published: April 2023

Figure S1 provides a visualization of the genetic ancestry of the cohort
Table S2 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Authors: Zhang Wei , Liu Bo , Wu Wenhui , Li Likun , Broom Bradley M. , Basourakos Spyridon P. , Korentzelos Dimitrios , Luan Yang , Wang Jianxiang , Yang Guang , Park Sanghee , Azad Abul Kalam , Cao Xuhong , Kim Jeri , Corn Paul G. , Logothetis Christopher J. , Aparicio Ana M. , Chinnaiyan Arul M. , Navone Nora , Troncoso Patricia , Thompson Timothy C.
Published: April 2023

Differential expression result for Beltran's 70 classifier genes in PDX RNAseq dataset.
Table S2 from Expression and Therapeutic Potential of SOX9 in Chordoma
Authors: Chen Hua , Garbutt Cassandra C. , Spentzos Dimitrios , Choy Edwin , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

Summary of the clinicopathological characteristics of chordoma patients
Supplementary Tables, Supplementary Figure Legend and Supplementary Figures from Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Authors: Weiss Glen J. , Beck Julia , Braun Donald P. , Bornemann-Kolatzki Kristen , Barilla Heather , Cubello Rhiannon , Quan Walter , Sangal Ashish , Khemka Vivek , Waypa Jordan , Mitchell William M. , Urnovitz Howard , Schütz Ekkehard
Published: April 2023

Supplementary Tables, Supplementary Figure Legend and Supplementary Figures SUPPLEMENTARY TABLE,1:DISCOVERY COHORT (n=23) SUPPLEMENTARY TABLE,2:VALIDATION COHORT (n=33)
Figure S1-2 from Expression and Therapeutic Potential of SOX9 in Chordoma
Authors: Chen Hua , Garbutt Cassandra C. , Spentzos Dimitrios , Choy Edwin , Hornicek Francis J. , Duan Zhenfeng
Published: April 2023

Supplementary Figure S1: (A) Co-incubation of 10nM SOX9 siRNA with increasing concentrations of doxorubicin increased anti-cancer effects in U-CH1 and CH22 cell lines as determined by the MTT assay. (B) As shown in the MTT assay, co-incubation of 10nM of SOX9 siRNA with increasing concentrations of cisplatin exhibited a slight positive influence on anti-cancer effects in U-CH1 and CH22 cell lines; Supplementary Figure S2: Model for targeting SOX9 to regulate cell proliferation, apoptosis and cell cycle in chordoma. Inhibition of SOX9 by RNAi had the following effects: reduced cell proliferation and migration; induced apoptosis and cell cycle arrest; and a decreased presence of cancer stem cell markers.
Supplementary materials and methods from The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis
Authors: Xu Lei , Mao Xueying , Guo Tianyu , Chan Pui Ying , Shaw Greg , Hines John , Stankiewicz Elzbieta , Wang Yuqin , Oliver R. Tim D. , Ahmad Amar Sabri , Berney Daniel , Shamash Jonathan , Lu Yong-Jie
Published: April 2023

Additional clinical information of samples, details of antibodies used in immunofluorescence and probes in FISH.
Table S3 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Significantly Differentially Expressed miRNAs between UCN and Normal
Table S2 from miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD
Authors: Pekow Joel , Meckel Katherine , Dougherty Urszula , Huang Yong , Chen Xindi , Almoghrabi Anas , Mustafi Reba , Ayaloglu-Butun Fatma , Deng Zifeng , Haider Haider I. , Hart John , Rubin David T. , Kwon John H. , Bissonnette Marc
Published: April 2023

Significantly Differentially Expressed miRNAs between UC and Normal
Supplementary Figure 4 from Integrative Systemic and Local Metabolomics with Impact on Survival in High-Grade Serous Ovarian Cancer
Authors: Bachmayr-Heyda Anna , Aust Stefanie , Auer Katharina , Meier Samuel M. , Schmetterer Klaus G. , Dekan Sabine , Gerner Christopher , Pils Dietmar
Published: April 2023

Log2 concentrations of all 89 GPhLs. Subdivided into healthy controls (blue) and each the four most extreme patients (green, with the highest and red, with the lowest GPhL concentrations), sorted from top to bottom according concentration levels. Significant OS-associated GPhLs are labeled in bold.
Supplemental Figure Legends from Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial
Authors: Exley Mark A. , Friedlander Phillip , Alatrakchi Nadia , Vriend Lianne , Yue Simon , Sasada Tetsuro , Zeng Wanyong , Mizukami Yo , Clark Justice , Nemer David , LeClair Kenneth , Canning Christine , Daley Heather , Dranoff Glenn , Giobbie-Hurder Anita , Hodi F. Stephen , Ritz Jerome , Balk Steven P.
Published: April 2023

Supplemental Figure Legends
Time lapse NKG2D-CAR memory T cells vs MG-63 cells from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

Time-lapse: NKG2D-CAR Memory T cells target osteosarcoma cells
Table S5 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

NKG2DL expression on healthy cells.
Supplementary Fig. 1 from Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Ashizawa Tadashi , Iizuka Akira , Nonomura Chizu , Kondou Ryota , Maeda Chie , Miyata Haruo , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Katano Ikumi , Ito Mamoru , Akiyama Yasuto
Published: April 2023

High expression levels of phospho-STAT3 and PD-L1 proteins in the SCC-3 cell line
Figure S2 from Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells
Authors: Fernández Lucía , Metais Jean-Yves , Escudero Adela , Vela María , Valentín Jaime , Vallcorba Isabel , Leivas Alejandra , Torres Juan , Valeri Antonio , Patiño-García Ana , Martínez Joaquín , Leung Wing , Pérez-Martínez Antonio
Published: April 2023

NKG2D-CAR memory T cells persist in the peripheral blood of treated mice for up to 21 days.
Supplementary Table S1 from Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Authors: Streby Keri A. , Geller James I. , Currier Mark A. , Warren Patrick S. , Racadio John M. , Towbin Alexander J. , Vaughan Michele R. , Triplet Melinda , Ott-Napier Kristy , Dishman Devon J. , Backus Lori R. , Stockman Beth , Brunner Marianne , Simpson Kathleen , Spavin Robert , Conner Joe , Cripe Timothy P.
Published: April 2023

Supplementary Table S1. Dose administered based on post-injection titers.
A041-04 DART PART 1 FINAL 21Sept2016 Supp from The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Authors: Voss Martin H. , Bhatt Rupal S. , Plimack Elizabeth R. , Rini Brian I. , Alter Robert S. , Beck J. Thaddeus , Wilson Dawn , Zhang Xiaosha , Mutyaba Musa , Glasser Chad , Attie Kenneth M. , Sherman Matthew L. , Pandya Shuchi S. , Atkins Michael B.
Published: April 2023

Supplemental data for DART Part 1 manuscript. Contains 1 figure and 3 tables. Supplemental Figure 1: Percent change from baseline in serum receptor expression. Samples were taken at cycle 1 day 1 (baseline), cycle 2 day 1, cycle 2 day 8, cycle 3 day 1, and the last visit. Percent change from baseline was calculated for each patient and averaged across all patients. (A) Serum VEGFR3 receptor expression (B) Serum VEGFR2 receptor expression. Supplemental Table 1: Management of Adverse Events Related to Dalantercept/Placebo Supplemental Table 2: Summary Pharmacokinetic Parameters for Dalantercept plus Axitinib Supplemental Table 3: Biomarker Expression Levels in Biopsied Tissue Samples
Supplementary Table S6 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S6: Comparative analysis of the mutational frequencies of genes affecting selected functional pathways in metaplastic breast cancers and triple-negative invasive ductal carcinomas of no special type and correlations of mutational status with clinicopathologic parameters. p<0.05 are highlighted in bold. *: Fisher's exact test. **: Mann-Whitney U-test.
Supplementary Table S2 from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S2: List of somatic mutations identified in the cohort of 35 metaplastic breast cancers and list of primers used for validation with Sanger sequencing of selected mutations.
Supplementary figure legend from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
Authors: Sinnott Jennifer A. , Peisch Sam F. , Tyekucheva Svitlana , Gerke Travis , Lis Rosina , Rider Jennifer R. , Fiorentino Michelangelo , Stampfer Meir J. , Mucci Lorelei A. , Loda Massimo , Penney Kathryn L.
Published: April 2023

Supplementary figure legend